Eli Lilly inked two collaborations on Monday, one focused on cardiometabolic diseases with South Korea’s OliX Pharmaceuticals ...

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...